Related Experiment Video
Updated: Jun 2, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation
Alois Gratwohl1, Ronald Brand, Dietger Niederwieser
1European Group for Blood and Marrow Transplantation Activity Survey Office, University Hospital, Basel, Switzerland. hematology@uhbs.ch
Insights
The Joint Accreditation Committee International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation (JACIE) accreditation improved patient survival in hematopoietic stem-cell transplantation (HSCT). This quality management system enhanced outcomes for both allogeneic and autologous HSCT procedures.
Area of Science:
- Hematology
- Transplantation Medicine
- Quality Management
Background:
- Hematopoietic stem-cell transplantation (HSCT) is a critical treatment for hematologic disorders.
- Ensuring high-quality care in HSCT is essential for patient outcomes.
- The Joint Accreditation Committee International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation (JACIE) was established to standardize and improve HSCT quality.
Purpose of the Study:
- To evaluate the impact of JACIE accreditation on patient survival after HSCT.
- To test the hypothesis that implementing a comprehensive quality management system improves HSCT outcomes.
Main Methods:
- Analysis of data from 41,623 allogeneic and 66,281 autologous HSCTs performed between 1999-2007 across 421 European teams.
- Outcomes were assessed at different stages relative to JACIE accreditation: baseline, preparation, application, and post-accreditation.
- Statistical analysis was clustered by team and stratified by year, donor type, disease, conditioning, and country's gross national income, adjusting for European Group for Blood and Marrow Transplantation scores.
Main Results:
- Patient outcomes significantly improved with more advanced stages of JACIE accreditation.
- Relapse-free survival showed improvement after JACIE accreditation for allogeneic HSCT (HR 0.86, P=.01) and autologous HSCT (HR 0.83, P<.01) compared to baseline.
- These improvements were consistent across various risk factors and transplantation years.
Conclusions:
- The introduction of a comprehensive clinical quality management system like JACIE is associated with improved patient outcomes in HSCT.
- Findings support the hypothesis that standardized quality management positively impacts HSCT success rates.
- Observational data suggest JACIE accreditation contributes to better patient survival and reduced relapse rates.
Purpose:
A comprehensive quality management system called JACIE (Joint Accreditation Committee International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation), was introduced to improve quality of care in hematopoietic stem-cell transplantation (HSCT). We therefore tested the hypothesis that the introduction of JACIE improved patient survival.
Patients And Methods:
Data on 41,623 allogeneic (39%) and 66,281 autologous (61%) HSCTs for an acquired hematologic disorder performed between 1999 and 2007 by 421 teams in Europe were used to assess the outcomes of patients who received a transplantation at baseline (> 3 years before application or no application), during preparation (3 years before application), during application (time from application to accreditation), and after JACIE accreditation. The analysis was clustered by team and stratified for year of HSCT, donor type, disease, conditioning, and gross national income per capita of the respective country. Patient's risks were adjusted for by their European Group for Blood and Marrow Transplantation score.
Results:
Patient outcome was systematically better when the transplantation center was at a more advanced phase of JACIE accreditation, independent of year of transplantation and other risk factors. Improvement was robust as quantified for relapse-free survival after allogeneic HSCT compared with baseline by a hazard ratio (HR) of 0.96 (95% CI, 0.90 to 1.03; P = .22) for preparation, 0.95 (95% CI, 0.88 to 1.03; P = .20) for application, and 0.86 (95% CI, 0.78 to 0.95; P = .01) for the accreditation (test for trend P = .01). Improvement from baseline was similar after autologous HSCT (HR for accreditation, 0.83; 95% CI, 0.74 to 0.93; P < .01).
Conclusion:
Even with all the limitations of an observational study, these findings support the hypothesis that introduction of a comprehensive clinical quality management system is associated with improved outcome of patients after HSCT.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Multipotency of Hematopoietic Stem Cells
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

